Anavex Life Sciences Corp (AVXL)

[nidan7500]

Xena:[quoteAssociate Professor Stephen Macfarlane, Head of HammondCare Clinical Services, is the principal investigator of the trial.

“We’re still not sure what causes Alzheimer’s disease, but the prevailing theory is the brain is damaged by a build-up of toxic proteins,” A/Prof Macfarlane said.

“There have been many failed trials attempting to remove these proteins or prevent them being produced.

“The theory behind Anavex 2-73 is that it targets a receptor that, when activated, leads to the removal of these abnormal proteins from brain cells.”

The Phase II trial of the drug, featuring 32 patients across Victoria, found their mini mental state exam (MMSE) score remained essentially unchanged after 18 months. The degree of decline expected in a person at a similar stage of Alzheimer’s disease is about two MMSE points per year.

Six of the patients also improved their MMSE scores significantly – an unprecedented outcome in Alzheimer’s treatment. This trial was extended from an initial six months to five years on the basis of the strength of the results and at the request of trial participants and their carers. ][/quote]

flashing back to the outputs from the BIIB PR team where the message has been …"still going downhill but at a slower pace"...my para...Cannot help but think what the BIIB PR team would do with the Dr. Mc F. quote above.